• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACELYRIN, INC. - Common Stock (NQ:SLRN)

2.270 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ACELYRIN, INC. - Common Stock

< Previous 1 2 3 Next >
3 Biopharmaceutical Stocks Bucking the Sell-Off
April 10, 2025
Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence. 
Via MarketBeat
Topics World Trade
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week
February 23, 2025
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments. 
Via Stocktwits
These stocks are moving in today's pre-market session
February 21, 2025
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
Wondering what's happening in today's after-hours session?
February 20, 2025
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Earnings Scheduled For November 13, 2024
November 13, 2024
 
Via Benzinga
Earnings Preview: Acelyrin
November 12, 2024
 
Via Benzinga
SLRN Stock Earnings: Acelyrin Misses EPS for Q2 2024
August 13, 2024
SLRN stock results show that Acelyrin missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Nasdaq Down 1.5%; RPM Posts Upbeat Results
January 07, 2025
 
Via Benzinga
Dow Surges Over 100 Points; US Trade Deficit Widens In November
January 07, 2025
 
Via Benzinga
Topics Stocks
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
January 07, 2025
 
Via Benzinga
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
January 07, 2025
 
Via Benzinga
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
May 15, 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
March 28, 2024
SLRN stock results show that Acelyrin beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
What 5 Analyst Ratings Have To Say About Acelyrin
November 28, 2023
 
Via Benzinga
What's Going On With ACELYRIN Shares Friday?
January 03, 2025
ACELYRIN shares are moving higher on Friday after the company announced that it will reveal Phase 2 data and announce Phase 3 plans for Subcutaneous Lonigutamab at a virtual investor event. 
Via Benzinga
Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday
January 03, 2025
 
Via Benzinga
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
December 11, 2024
 
Via Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
August 20, 2024
 
Via Benzinga
Acelyrin Cuts Workforce, Deprioritizes Former Lead Drug Izokibep
August 14, 2024
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab. 
Via Benzinga
Ouster Reports Weak Sales, Joins Brinker International And Other Big Stocks Moving Lower In Wednesday Pre-Market Session
August 14, 2024
 
Via Benzinga
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
July 08, 2024
 
Via Benzinga
Investors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease Patients
March 20, 2024
Acelyrin releases Phase 1/2 trial results of lonigutamab. Rapid improvements in eye bulge and double vision. Well-tolerated with no serious adverse events. Phase 2b/3 trial slated for the second half... 
Via Benzinga
Acelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis Study
March 11, 2024
Acelyrin reports positive Phase 2b/3 trial results for izokibep in psoriatic arthritis, achieving ACR50 at week 16 with high statistical significance. Long-term data in hidradenitis suppurativa show... 
Via Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
December 17, 2023
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now. 
Via InvestorPlace
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
November 28, 2023
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
Why Is Inflammation Disease Focused Acelyrin Stock Trading Lower Today?
November 28, 2023
Acelyrin Inc (NASDAQ: SLRN) updated its izokibep clinical development program, including its ongoing global Phase 2b/3 trial for izokibep in  
Via Benzinga
Acelyrin (SLRN) Q3 2023 Earnings Call Transcript
November 07, 2023
SLRN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
September 30, 2023
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars. 
Via InvestorPlace
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 21, 2023
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap